M&A activity
VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026
venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment
VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026
venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment
VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026
venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment
VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026
venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment
No public results for “Take the Biopharma Sentiment Index” Q1 2026 yet
Biopharma Sentiment Index; Q1 2026; biopharma executives; life sciences sentiment; 2026 outlook; M&A activity; AI in biopharma; geopolitical risk; survey data
From JP Morgan to the Next Wave: What’s Driving Biotech in 2026
J.P. Morgan Healthcare Conference; biotech trends 2026; M&A activity; oncology; neuropsychology; hematology; artificial intelligence; drug discovery; investment; regulatory science
Biotech Industry Prepares for Trump 2.0: Regulatory Changes and M&A Activity Expected
Biotech industry, Trump 2.0, FDA changes, M&A activity, regulatory environment, pharmaceutical industry, healthcare policy